Prognostic biological factors of radiation pneumonitis after stereotactic body radiation therapy combined with pulmonary perfusion imaging

Guo,Leiming; Ding,Gaofeng; Xu,Wencai; Lu,Yufei; Ge,Hong; Jiang,Yue; Chen,Xijuan; Li,Yin

doi:10.3892/etm.2018.6936

Prognostic biological factors of radiation pneumonitis after stereotactic body radiation therapy combined with pulmonary perfusion imaging

Authors:
- Leiming Guo
- Gaofeng Ding
- Wencai Xu
- Yufei Lu
- Hong Ge
- Yue Jiang
- Xijuan Chen
- Yin Li
View Affiliations

Affiliations: Department of Radiotherapy, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan 450000, P.R. China
Published online on: November 6, 2018 https://doi.org/10.3892/etm.2018.6936
Pages: 244-250

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Radiation pneumonitis (RP) is one of the most common dose‑limiting toxicity syndromes in patients with thoracic malignant tumors receiving radiotherapy. The present study aimed to identify biological factors for the prediction of RP. Pulmonary perfusion imaging is capable of reflecting the differential functional activity of various regions of the lung, and in the present study, radiotherapy plans that were established on the basis that pulmonary perfusion images have high biological conformality, which may identify regions vulnerable to RP to spare them from radiation. A total of 46 patients with non‑small cell lung cancer (NSCLC), exhibiting high and low levels of apurinic/apyrimidinic endonuclease‑1 (Ape‑1), intercellular adhesion molecule (ICAM)‑1 and interleukin (IL)‑17A prior to treatment, with SBRT with respective cut‑off values of 4.2, 3.0 and 5.1 µg/l were stratified into groups A and B. Patients received radiation doses within the margin of the planning target volume. Stereotactic body radiation therapy (SBRT) was used for the treatment of NSCLC and single‑photon emission computed tomography pulmonary perfusion imaging was used to assess all patients for the presence of RP. Furthermore, the serum levels of Ape‑1, ICAM‑1 and IL‑17A were examined by ELISA. Prior to SBRT, perfusion images indicated that no RP was present in any of the patients, and 23 patients had high levels of Ape‑1, ICAM‑1 and IL‑17A. After SBRT, 22 out of 23 patients in group A (95.65%) presented with RP and 1 patient (4.35%) had no RP. In group B, 6 out of 23 patients (26.09%) had RP and 17 patients (73.91%) had no RP after SBRT. The difference between the two groups in the incidence of RP was significant (P=1.66x10‑12 <0.05). In conclusion, high levels of Ape‑1, ICAM‑1 and IL‑17A are associated with an increased risk of RP. A further analysis should be performed in the future to verify whether these factors have significant prognostic value.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, Keijser A, Faivre-Finn C and Senan S: Use of thoracic radiotherapy for extensive stage small-cell lung cancer: A phase 3 randomised controlled trial. Lancet. 385:36–42. 2014. View Article : Google Scholar : PubMed/NCBI
3	Zimmermann FB, Geinitz H, Schill S, Grosu A, Schratzenstaller U, Molls M and Jeremic B: Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer. 48:107–114. 2005. View Article : Google Scholar : PubMed/NCBI
4	Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, El Naqa I, Hubbs JL, Lebesque JV, Timmerman RD, et al: Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys. 76 3 Suppl:S70–S76. 2010. View Article : Google Scholar : PubMed/NCBI
5	Vogelius IR and Bentzen SM: A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol. 51:975–983. 2012. View Article : Google Scholar : PubMed/NCBI
6	Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Karasawa K, Hayakawa K, Niibe Y, Takai Y, et al: Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: Can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 81:1352–1358. 2011. View Article : Google Scholar : PubMed/NCBI
7	Timmerman RD and Kavanagh BD: Stereotactic body radiation therapy. Curr Probl Cancer. 29:120–157. 2005. View Article : Google Scholar : PubMed/NCBI
8	Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, et al: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 303:1070–1076. 2010. View Article : Google Scholar : PubMed/NCBI
9	Albain KS, Swann RS, Rusch VW, Turrisi AT III, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, et al: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet. 374:379–386. 2009. View Article : Google Scholar : PubMed/NCBI
10	Bradley JD, Hope A, El Naqa I, Apte A, Lindsay PE, Bosch W, Matthews J, Sause W, Graham MV and Deasy JO: RTOG: A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys. 69:985–992. 2007. View Article : Google Scholar : PubMed/NCBI
11	Liu GD, Xia L, Zhu JW, Ou S, Li MX, He Y, Luo W, Li J, Zhou Q, Yang XQ, et al: Genistein alleviates radiation-induced pneumonitis by depressing Ape-1/Ref-1 expression to down-regulate inflammatory cytokines. Cell Biochem Biophys. 69:725–733. 2014. View Article : Google Scholar : PubMed/NCBI
12	Darby SC, McGale P, Taylor CW and Peto R: Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 6:557–565. 2005. View Article : Google Scholar : PubMed/NCBI
13	Henson KE, McGale P, Taylor C and Darby SC: Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Br J Cancer. 108:179–182. 2013. View Article : Google Scholar : PubMed/NCBI
14	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
15	Harkenrider MM, Bertke MH, Dunlap NE and Dragun AE: Stereotactic body radiotherapy (SBRT) for non-pathologically diagnosed lung cancer patients. J Solid Tumors. 2:2012. View Article : Google Scholar
16	Tucker SL, Liu HH, Liao Z, Wei X, Wang S, Jin H, Komaki R, Martel MK and Mohan R: Analysis of radiation pneumonitis risk using a generalized Lyman model. Int J Radiat Oncol Biol Phys. 72:568–574. 2008. View Article : Google Scholar : PubMed/NCBI
17	Oh D, Ahn YC, Park HC, Lim DH and Han Y: Prediction of radiation pneumonitis following high-dose thoracic radiation therapy by 3 Gy/fraction for non-small cell lung cancer: Analysis of clinical and dosimetric factors. Jpn J Clin Oncol. 39:151–157. 2009. View Article : Google Scholar : PubMed/NCBI
18	Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, DiFilippo FP, Ficaro EP, Freeman MR, Hendel RC, Jain D, et al: Single photon-emission computed tomography. J Nucl Cardiol. 17:941–973. 2010. View Article : Google Scholar : PubMed/NCBI
19	Muehllehner G and Karp JS: Positron emission tomography. Phys Med Biol. 51:R117–R137. 2006. View Article : Google Scholar : PubMed/NCBI
20	Scott CB, Nelson JS, Farnan NC, Curran WJ Jr, Murray KJ, Fischbach AJ, Gaspar LE and Nelson DF: Central pathology review in clinical trials for patients with malignant glioma. A Report of Radiation Therapy Oncology Group 83-02. Cancer. 76:307–313. 1995. View Article : Google Scholar : PubMed/NCBI
21	Crabtree TD, Denlinger CE, Meyers BF, El Naqa I, Zoole J, Krupnick AS, Kreisel D, Patterson GA and Bradley JD: Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 140:377–386. 2010. View Article : Google Scholar : PubMed/NCBI
22	Mehta V: Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys. 63:5–24. 2005. View Article : Google Scholar : PubMed/NCBI
23	Sura S, Gupta V, Yorke E, Jackson A, Amols H and Rosenzweig KE: Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol. 87:17–23. 2008. View Article : Google Scholar : PubMed/NCBI
24	Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu CS, Mohan R, Cox JD and Komaki R: Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys. 66:1399–1407. 2006. View Article : Google Scholar : PubMed/NCBI
25	Claude L, Pérol D, Ginestet C, Falchero L, Arpin D, Vincent M, Martel I, Hominal S, Cordier JF and Carrie C: A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: Clinical and dosimetric factors analysis. Radiother Oncol. 71:175–181. 2004. View Article : Google Scholar : PubMed/NCBI
26	Tell G, Damante G, Caldwell D and Kelley MR: The intracellular localization of APE-1/Ref-1: More than a passive phenomenon? Antioxid Redox Signal. 7:367–384. 2005. View Article : Google Scholar : PubMed/NCBI
27	Angkeow P, Deshpande SS, Qi B, Liu YX, Park YC, Jeon BH, Ozaki M and Irani K: Redox factor-1: An extra-nuclear role in the regulation of endothelial oxidative stress and apoptosis. Cell Death Differ. 9:717–725. 2002. View Article : Google Scholar : PubMed/NCBI
28	Linard C, Marquette C, Mathieu J, Pennequin A, Clarençon D and Mathé D: Acute induction of inflammatory cytokine expression after gamma-irradiation in the rat: Effect of an NF-kappaB inhibitor. Int J Radiat Oncol Biol Phys. 58:427–434. 2004. View Article : Google Scholar : PubMed/NCBI
29	Haase MG, Klawitter A, Geyer P, Alheit H, Baumann M, Kriegel TM, Kasper M and Baretton GB: Sustained elevation of NF-kappaB DNA binding activity in radiation-induced lung damage in rats. Int J Radiat Biol. 79:863–877. 2003. View Article : Google Scholar : PubMed/NCBI
30	Ando K, Hirao S, Kabe Y, Ogura Y, Sato I, Yamaguchi Y, Wada T and Handa H: A new APE-1/Ref-1-dependent pathway leading to reduction of NF-kappaB and AP-1, and activation of their DNA-binding activity. Nucleic Acids Res. 36:4327–4336. 2008. View Article : Google Scholar : PubMed/NCBI
31	Thakur S, Sarkar B, Cholia RP, Gautam N, Dhiman M and Mantha AK: APE1/Ref-1 as an emerging therapeutic target for various human diseases: Phytochemical modulation of its functions. Exp Mol Med. 46:e1062014. View Article : Google Scholar : PubMed/NCBI
32	Tell G, Quadrifoglio F, Tiribelli C and Kelley MR: The many functions of APE1/Ref-1: Not only a DNA repair enzyme. Antioxid Redox Signal. 11:601–620. 2009. View Article : Google Scholar : PubMed/NCBI
33	Koukourakis MI: Radiation damage and radioprotectants: New concepts in the era of molecular medicine. Br J Radiol. 85:313–330. 2012. View Article : Google Scholar : PubMed/NCBI
34	Fox J and Haston CK: CXC receptor 1 and 2 and neutrophil elastase inhibitors alter radiation-induced lung disease in the mouse. Int J Radiat Oncol Biol Phys. 85:215–222. 2013. View Article : Google Scholar : PubMed/NCBI
35	Wang LP, Wang YW, Wang BZ, Sun GM, Wang XY and Xu JL: Expression of interleukin-17A in lung tissues of irradiated mice and the influence of dexamethasone. ScientificWorldJournal. 2014:2510672014.PubMed/NCBI
36	Wang BZ, Wang LP, Han H, Cao FL, Li GY, Xu JL, Wang XW and Wang LX: Interleukin-17A antagonist attenuates radiation-induced lung injuries in mice. Exp Lung Res. 40:77–85. 2014. View Article : Google Scholar : PubMed/NCBI